atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic, thromboembolic disease
DISEASE INTERVENTION COMPARISON RESULTS
Ann Intern Med. 2012 Dec 4;157(11):796-807 Systematic Review
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic, thromboembolic disease The Use of
anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban
As Treatment, Chronic
Is better Than
anticoagulants, antivitamine K, warfarin
To reduce mortality in atrial fibrillation (RR 0.88) but not in venous thromboembolism. Fatal bleeding was reduced (RR 0.60) but not major bleeding and bleeding risk may be increased in older people
Circulation. 2015 Jul 21;132(3):194-204 Systematic Review
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic, thromboembolic disease, old patients The Use of
anticoagulants, oral direct thrombin inhibitors, dabigatran, oral factor Xa inhibitors, apixaban, rivaroxaban, edoxaban
As Treatment, Chronic
Is equal Than
anticoagulants, antivitamine K, warfarin
To reduce thrombo-embolic events, but with different bleeding patterns: dabigatran was associated with a higher risk of gastrointestinal bleeding, risk of intracranial bleeding was lower, apixaban and edoxaban associated lower risk of major bleedings